LAWRENCE, Mass., Nov. 1, 2017 /PRNewswire/ -- NxStage Medical,
Inc. (Nasdaq: NXTM), a leading medical technology
company focused on advancing renal care, today announced new
findings in a series of compelling research abstracts
demonstrating, and further validating, the importance of more
frequent home hemodialysis.
"NxStage is represented by 11 accepted abstracts evaluating home
hemodialysis, treatment frequency, and peritoneal dialysis," said
Joe Turk, President, NxStage
Medical, Inc. "Additionally, we are thrilled that a total of 33
abstracts about home hemodialysis and hemodialysis frequency are
being evaluated and discussed at such an important congress."
The collection of data will be presented at the American Society
of Nephrology (ASN) Congress being held October 31 – November 5,
2017, in New Orleans,
LA.
Two oral presentations confirm findings from previously
published interim analyses of the FREEDOM study of daily home
hemodialysis: specifically, that frequent home hemodialysis
coincided with dramatic reductions in post-treatment recovery time
and broad improvements in both physical and mental health-related
quality of life. Another abstract finds that nocturnal home
hemodialysis is associated with greater retention of home
hemodialysis patients compared to daytime treatment. Four other
oral presentations will also address aspects of home hemodialysis
and hemodialysis frequency.
"Data continues to affirm the benefits of frequent home
hemodialysis by showing continued improvements in patient-centered
outcomes," said, Dr. Eric Weinhandl,
PhD, MS, NxStage Clinical Epidemiologist and Adjunct Assistant
Professor of Pharmaceutical Care & Health Systems at the
University of Minnesota. "We are excited to be sharing this
data at ASN Kidney Week and to continue the conversation about the
importance of individualized dialysis therapy and improving access
to therapy in the home."
Five posters will also be presented, including data that
demonstrate higher home hemodialysis training graduation rates in
patients using the Nx2me Connected Health® iPad® application.
Oral presentations will be made by experts in the industry on
both Thursday, November 2, in Room
290 beginning at 4:30 PM and
Friday, November 3, Room 295,
beginning at 4:30 PM.
Full abstracts can be read online at
https://www.asn-online.org/abstracts/.
Conference attendees can also meet with NxStage representatives
in booth 1127 to discuss the most recent publications.
Visit www.NxStage.com for more information about therapy
options with the NxStage® System One™.
The NxStage System One is a prescription device and, like all
medical devices, involves some risks. The risks associated with
hemodialysis treatments in any environment include, but are not
limited to, high blood pressure, fluid overload, low blood
pressure, heart-related issues, and vascular access complications.
The medical devices used in hemodialysis therapies may add
additional risks including air entering the bloodstream, and blood
loss due to clotting or accidental disconnection of the blood
tubing set. Patients should consult with their doctor to understand
the risks and responsibilities of home and/or more frequent
hemodialysis using the NxStage System One. Additionally, the
reported benefits of home and/or more frequent hemodialysis may not
be experienced by all patients. Patients and providers are
encouraged to contact their state regulators to discuss
state-specific regulations that may impact dialysis in the skilled
nursing facility setting.
About the NxStage System One
The NxStage System One is
the first and only truly portable hemodialysis system cleared
specifically by the FDA for home hemodialysis, home nocturnal
hemodialysis and solo home hemodialysis. Its simplicity and
revolutionary size (just over a foot tall) are intended to allow
convenient use in patients' homes and give patients the freedom to
travel with their therapy. When combined with the NxStage PureFlow
SL Dialysis Preparation System, patients are able to further
simplify, using ordinary tap water to create dialysis fluid on
demand. Unlike conventional hemodialysis systems, the System One
requires no special infrastructure to operate. Under the guidance
of their physician, patients can use the NxStage System One, with
their trained partners (or for patients prescribed to receive solo
dialysis, alone), where, how and when it best meets their needs,
including while they are sleeping - at home or on vacation and at a
medically appropriate treatment frequency. In addition, NxStage's
Nx2me Connected Health platform collects important NxStage System
One and patient information for flexible viewing, monitoring and
reporting that may improve patient management and patient
retention, as well as simplify alternative site care.
www.nxstage.com.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical
technology company, headquartered in Lawrence, Massachusetts, USA, that develops,
manufactures and markets innovative products for the treatment of
ESRD and acute kidney failure. NxStage also has established a small
number of dialysis clinics committed to the development of
innovative care delivery models for patients with ESRD. For more
information on NxStage and its products and services, please visit
the Company's websites at www.nxstage.com and
www.nxstagekidneycare.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements contained in this release that are not clearly
historical in nature are forward-looking, and the words
"anticipate," "believe," "expect," "estimate," "plan," and similar
expressions are generally intended to identify forward-looking
statements. Actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors including those that are discussed in
NxStage's filings with the Securities and Exchange Commission,
including its Quarterly Report on Form 10-Q for the quarter ended
June 30, 2017. NxStage is under no
obligation to (and expressly disclaims any such obligation to)
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
Media contact:
Kristen K. Sheppard, Esq.
ksheppard@nxstage.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/eleven-unique-nxstage-abstracts-accepted-for-2017-kidney-week-300547757.html
SOURCE NxStage Medical, Inc.